Zevra Denmark A/S: Financial statements 2025
CVR: 43259326
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Zevra Denmark A/S (CVR 43259326) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 123,335,000 and a net result of DKK 334,468,000 compared with DKK -132,114,000 the year before. That is an increase of 73.8% compared with the year before. The profit margin was 271.2%. Equity in the 2025 report amounted to DKK 174,841,000. The solvency ratio was 32.5%. The company had 4 employees in the financial year.
- Revenue
- DKK 123,335,000
- Gross Profit
- DKK 404,024,000
- Profit/Loss
- DKK 334,468,000
- Equity
- DKK 174,841,000
- Total Assets
- DKK 538,365,000
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 123.3M | 404M | 334.5M | 174.8M | 4 |
| 2024 | 71M | -1.7M | -132.1M | -159.6M | 4 |
| 2023 | - | -12.5M | -20.5M | -27.5M | 6 |
Official annual report
How creditworthy is Zevra Denmark A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of December 31, 2025, Timothy Sangiovanni has joined the board of directors of Zevra Denmark A/S.
As of December 31, 2025, Raymond La Duane Clifton has left the board of directors of Zevra Denmark A/S.
As of December 31, 2025, Timothy Sangiovanni is registered as adm. dir. of Zevra Denmark A/S.
As of December 31, 2025, Raymond La Duane Clifton has stepped down as adm. dir. of Zevra Denmark A/S.
Zevra Denmark A/S has published its annual report for 2024. Revenue came to DKK 70,973,000, and the net result was DKK -132,114,000.
As of July 16, 2025, Rahsaan Waleed Thompson has joined the board of directors of Zevra Denmark A/S.
As of July 16, 2025, Neil McFarlane has left the board of directors of Zevra Denmark A/S.
About Zevra Denmark A/S
Zevra Denmark A/S is a Danish company of the type Aktieselskab based in Frederiksberg, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named KemPharm Denmark A/S. The management consists of Timothy Sangiovanni. The board consists of Rahsaan Waleed Thompson (chair), Justin Andrew Renz, Thomas Weitemeyer and Timothy Sangiovanni. The company is owned by Zevra Therapeutics, Inc.. The company has 4 employees (2026). In 2025, the company reported revenue of DKK 123,335,000 and a net result of DKK 334,468,000 compared with DKK -132,114,000 the year before. Equity in the 2025 report amounted to DKK 174,841,000.